



# Human Anti-SARS-CoV-2 Spike NTD Monoclonal antibody, clone 3257 (CABT-CS084)

This product is for research use only and is not intended for diagnostic use.

## PRODUCT INFORMATION

<b>Specificity</b>	Recognize an epitope on SARS-CoV2 Spike Protein NTD subdomain. Furthermore, it does not cross react with the receptor-binding domain (RBD) region of the S1 protein or the original SARS-CoV virus.
<b>Target</b>	SARS-CoV-2 Spike NTD
<b>Immunogen</b>	Sequenced from human survivors of COVID-19 (SARS-CoV-2)
<b>Isotype</b>	IgG1
<b>Source/Host</b>	Humanized
<b>Species Reactivity</b>	SARS-CoV-2
<b>Clone</b>	3257
<b>Purification</b>	>95% by SDS Page
<b>Conjugate</b>	unconjugated
<b>Applications</b>	ELISA, IHC
<b>Format</b>	Liquid
<b>Size</b>	100 µg, 500 µg
<b>Buffer</b>	0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl
<b>Preservative</b>	None

**Storage**

This monoclonal antibody is stable for at least one month when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.

---

## BACKGROUND

**Introduction**

The Coronavirus (CoV) disease 2019 (COVID-19) is caused by severe acute respiratory syndrome (SARS)-CoV-2 (also known as 2019-nCoV). The SARS-CoV2 Spike Protein consists of the S1 and S2 domains. The S1 can be further divided into an N-terminal domain (NTD) and a C-terminal domain (CTD), both of which can function as a receptor-binding entity. Vaccine and therapeutic development are targeting portions of the spike protein, including the NTD portion.

---

**Keywords**

SARS-CoV-2 Spike NTD; SARS-CoV-2; SARS-CoV-2 S1 NTD; SARS-CoV-2 S1; SARS-CoV-2 NTD

---